知识产权对印度制药行业的影响
Virendra S Gomase1,2, Suchita P Dhamane1, Swati C Jagdale3
1Department of Pharmaceutics, Jayawantrao Sawant College of Pharmacy and Research, Savitribai Phule Pune University, Pune, 411028, India.
Recent patents on biotechnology
|April 23, 2025
概括
印度 印度 印度
科学领域:
- 制药行业 制药行业 制药行业
- 知识产权法 知识产权法
- 专利法 专利法 专利法
背景情况:
- 印度制药行业利用工艺专利扩大全球市场,提供负担得起的仿制药.
- 印度的专利法发生了显著的发展,特别是在知识产权和TRIPS协议方面.
- 产品专利保护的历史性缺乏影响了印度制药行业的增长.
研究的目的:
- 分析印度专利制度的演变及其对制药业的影响.
- 审查TRIPS协议后印度专利起诉的挑战和变化.
- 了解印度努力使其专利制度与国际标准保持一致.
主要方法:
- 分析印度专利立法,包括修正案和条例.
- 审查TRIPS协议对印度专利法的影响.
- 审查专利起诉程序,包括授权前的反对意见.
主要成果:
- 引入产品专利保护和对专利法的修正旨在使印度与TRIPS协议标准保持一致.
- 专利起诉系统经历了渐进的变化,解决了诸如连续授权前反对意见等挑战.
- 印度正在积极努力加强知识产权执法和鼓励技术发展.
结论:
- 印度专利法的修正案使该系统现代化,并改善了对国际协议的遵守.
- 不断变化的专利环境为印度制药行业带来了机遇和挑战.
- 印度对知识产权的承诺对于促进创新和全球竞争力至关重要.
相关概念视频
Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
Drug Control Governance: Regulatory Bodies and Their Impact
119
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
119
Bioequivalence: Overview
875
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
875
Biopharmaceutics and Pharmacokinetics: Overview
1.7K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.7K
Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K
Pharmacovigilance
739
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
739


